Arbutus to participate in jefferies global healthcare conference

Warminster, pa., may 29, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that the arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in new york:
ABUS Ratings Summary
ABUS Quant Ranking